Research programme: PC-DAC:Insulin - ConjuChem
Alternative Names: CJC-1525; CJC-1525/CJC-1575; CJC-1575; PC-DAC™:Insulin; PC-InsulinLatest Information Update: 04 Nov 2017
At a glance
- Originator ConjuChem Biotechnologies
- Developer ConjuChem
- Class Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC, Injection)
- 30 Aug 2011 Preclinical development is ongoing in USA
- 30 Aug 2011 ConjuChem Biotechnologies relaunched as ConjuChem LLC